vs

Side-by-side financial comparison of James River Group Holdings, Inc. (JRVR) and UNITED STATES LIME & MINERALS INC (USLM). Click either name above to swap in a different company.

James River Group Holdings, Inc. is the larger business by last-quarter revenue ($167.7M vs $87.9M, roughly 1.9× UNITED STATES LIME & MINERALS INC). UNITED STATES LIME & MINERALS INC runs the higher net margin — 34.7% vs 19.1%, a 15.6% gap on every dollar of revenue. On growth, James River Group Holdings, Inc. posted the faster year-over-year revenue change (32.4% vs 9.8%). UNITED STATES LIME & MINERALS INC produced more free cash flow last quarter ($25.7M vs $-23.6M). Over the past eight quarters, UNITED STATES LIME & MINERALS INC's revenue compounded faster (10.8% CAGR vs -8.7%).

James River Corporation was an American pulp and paper company based in Richmond, Virginia, once the largest paper manufacturer in the world.

United States Lime & Minerals Inc is a leading US-based natural resources enterprise that produces high-calcium lime, dolomitic lime, limestone and related mineral products. Its core client segments cover infrastructure construction, steel manufacturing, agricultural soil amendment, environmental emission control and industrial processing, serving customers across North America.

JRVR vs USLM — Head-to-Head

Bigger by revenue
JRVR
JRVR
1.9× larger
JRVR
$167.7M
$87.9M
USLM
Growing faster (revenue YoY)
JRVR
JRVR
+22.5% gap
JRVR
32.4%
9.8%
USLM
Higher net margin
USLM
USLM
15.6% more per $
USLM
34.7%
19.1%
JRVR
More free cash flow
USLM
USLM
$49.2M more FCF
USLM
$25.7M
$-23.6M
JRVR
Faster 2-yr revenue CAGR
USLM
USLM
Annualised
USLM
10.8%
-8.7%
JRVR

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
JRVR
JRVR
USLM
USLM
Revenue
$167.7M
$87.9M
Net Profit
$32.1M
$30.5M
Gross Margin
48.0%
Operating Margin
14.6%
41.0%
Net Margin
19.1%
34.7%
Revenue YoY
32.4%
9.8%
Net Profit YoY
149.5%
13.2%
EPS (diluted)
$0.59
$1.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JRVR
JRVR
USLM
USLM
Q4 25
$167.7M
$87.9M
Q3 25
$172.7M
$102.0M
Q2 25
$174.8M
$91.5M
Q1 25
$172.3M
$91.3M
Q4 24
$126.7M
$80.1M
Q3 24
$191.5M
$89.4M
Q2 24
$188.3M
$76.5M
Q1 24
$201.1M
$71.7M
Net Profit
JRVR
JRVR
USLM
USLM
Q4 25
$32.1M
$30.5M
Q3 25
$1.0M
$38.8M
Q2 25
$4.8M
$30.8M
Q1 25
$9.6M
$34.1M
Q4 24
$-64.8M
$27.0M
Q3 24
$-39.4M
$33.4M
Q2 24
$7.6M
$26.1M
Q1 24
$15.4M
$22.4M
Gross Margin
JRVR
JRVR
USLM
USLM
Q4 25
48.0%
Q3 25
51.2%
Q2 25
45.8%
Q1 25
50.6%
Q4 24
44.3%
Q3 24
48.2%
Q2 24
45.5%
Q1 24
42.7%
Operating Margin
JRVR
JRVR
USLM
USLM
Q4 25
14.6%
41.0%
Q3 25
1.5%
45.3%
Q2 25
4.2%
39.0%
Q1 25
9.3%
43.7%
Q4 24
-57.0%
38.8%
Q3 24
-27.1%
42.6%
Q2 24
10.7%
39.1%
Q1 24
16.4%
35.9%
Net Margin
JRVR
JRVR
USLM
USLM
Q4 25
19.1%
34.7%
Q3 25
0.6%
38.0%
Q2 25
2.7%
33.7%
Q1 25
5.6%
37.4%
Q4 24
-51.1%
33.7%
Q3 24
-20.6%
37.3%
Q2 24
4.0%
34.0%
Q1 24
7.7%
31.3%
EPS (diluted)
JRVR
JRVR
USLM
USLM
Q4 25
$0.59
$1.06
Q3 25
$-0.02
$1.35
Q2 25
$0.06
$1.07
Q1 25
$0.16
$1.19
Q4 24
$-2.44
$-2.20
Q3 24
$-1.10
$1.16
Q2 24
$0.13
$0.91
Q1 24
$0.35
$3.92

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JRVR
JRVR
USLM
USLM
Cash + ST InvestmentsLiquidity on hand
$260.9M
$371.1M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$538.2M
$630.8M
Total Assets
$4.9B
$681.0M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JRVR
JRVR
USLM
USLM
Q4 25
$260.9M
$371.1M
Q3 25
$238.8M
$349.5M
Q2 25
$220.0M
$319.9M
Q1 25
$279.4M
$300.6M
Q4 24
$362.3M
$278.0M
Q3 24
$359.8M
$255.0M
Q2 24
$672.5M
$222.5M
Q1 24
$305.5M
$207.0M
Total Debt
JRVR
JRVR
USLM
USLM
Q4 25
$0
Q3 25
$0
Q2 25
$0
Q1 25
$0
Q4 24
$0
Q3 24
$0
Q2 24
$0
Q1 24
$0
Stockholders' Equity
JRVR
JRVR
USLM
USLM
Q4 25
$538.2M
$630.8M
Q3 25
$503.6M
$602.3M
Q2 25
$492.6M
$563.3M
Q1 25
$484.5M
$532.2M
Q4 24
$460.9M
$497.7M
Q3 24
$530.3M
$474.2M
Q2 24
$541.8M
$441.1M
Q1 24
$539.5M
$415.3M
Total Assets
JRVR
JRVR
USLM
USLM
Q4 25
$4.9B
$681.0M
Q3 25
$5.0B
$652.8M
Q2 25
$5.0B
$607.4M
Q1 25
$4.9B
$585.3M
Q4 24
$5.0B
$543.2M
Q3 24
$5.0B
$521.8M
Q2 24
$4.7B
$484.2M
Q1 24
$5.3B
$464.0M
Debt / Equity
JRVR
JRVR
USLM
USLM
Q4 25
0.00×
Q3 25
0.00×
Q2 25
0.00×
Q1 25
0.00×
Q4 24
0.00×
Q3 24
0.00×
Q2 24
0.00×
Q1 24
0.00×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JRVR
JRVR
USLM
USLM
Operating Cash FlowLast quarter
$-18.8M
$45.6M
Free Cash FlowOCF − Capex
$-23.6M
$25.7M
FCF MarginFCF / Revenue
-14.1%
29.2%
Capex IntensityCapex / Revenue
2.9%
22.6%
Cash ConversionOCF / Net Profit
-0.59×
1.49×
TTM Free Cash FlowTrailing 4 quarters
$-17.9M
$102.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JRVR
JRVR
USLM
USLM
Q4 25
$-18.8M
$45.6M
Q3 25
$34.3M
$45.9M
Q2 25
$25.2M
$34.0M
Q1 25
$-51.5M
$39.4M
Q4 24
$-247.1M
$38.6M
Q3 24
$-269.9M
$39.0M
Q2 24
$-8.7M
$21.2M
Q1 24
$24.1M
$27.2M
Free Cash Flow
JRVR
JRVR
USLM
USLM
Q4 25
$-23.6M
$25.7M
Q3 25
$33.7M
$31.3M
Q2 25
$24.7M
$20.8M
Q1 25
$-52.7M
$24.6M
Q4 24
$-252.0M
$27.6M
Q3 24
$-270.8M
$33.9M
Q2 24
$-9.3M
$16.8M
Q1 24
$23.3M
$20.3M
FCF Margin
JRVR
JRVR
USLM
USLM
Q4 25
-14.1%
29.2%
Q3 25
19.5%
30.7%
Q2 25
14.1%
22.7%
Q1 25
-30.6%
26.9%
Q4 24
-198.9%
34.4%
Q3 24
-141.4%
37.9%
Q2 24
-4.9%
21.9%
Q1 24
11.6%
28.4%
Capex Intensity
JRVR
JRVR
USLM
USLM
Q4 25
2.9%
22.6%
Q3 25
0.4%
14.4%
Q2 25
0.3%
14.5%
Q1 25
0.7%
16.3%
Q4 24
3.9%
13.8%
Q3 24
0.4%
5.8%
Q2 24
0.3%
5.7%
Q1 24
0.4%
9.5%
Cash Conversion
JRVR
JRVR
USLM
USLM
Q4 25
-0.59×
1.49×
Q3 25
33.61×
1.18×
Q2 25
5.29×
1.10×
Q1 25
-5.38×
1.16×
Q4 24
1.43×
Q3 24
1.17×
Q2 24
-1.14×
0.81×
Q1 24
1.56×
1.21×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JRVR
JRVR

Excess And Surplus Lines$156.7M93%
Specialty Admitted Insurance$10.9M7%

USLM
USLM

Segment breakdown not available.

Related Comparisons